$PIII
P3 Health Partners Inc. Stock $piii

$piii Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000155837022015155 Filed on October 21, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021 Q1
Revenue	$273.5M	$58.76M	$151.3M
YoY Change	80.8%	-52.94%
Cost Of Revenue	$265.8M	$200.1M
YoY Change		45.79%
Gross Profit	$7.724M	-$22.25M
YoY Change		79.74%
Gross Profit Margin	2.82%	-37.86%
Selling, General & Admin	$39.46M	$17.35M	$15.33M
YoY Change	157.44%	-0.81%
% of Gross Profit	510.96%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$590.5K	$187.6K	$332.5K
YoY Change	77.58%	3.14%
% of Gross Profit	7.65%
Operating Expenses	$325.7M	$117.7M	$480.0K
YoY Change	67756.68%	-7621.42%
Operating Profit	-$52.17M	-$58.89M	-$482.2K
YoY Change	10718.44%	444.57%
Interest Expense	-$2.761M	$2.131M
YoY Change		-168.91%
% of Operating Profit
Other Income/Expense, Net	-$8.623M	$949.7K	$5.301M
YoY Change	-262.65%	-426.73%
Pretax Income	-$60.79M	-$57.94M	$4.820M
YoY Change	-1361.21%	308.1%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income			0.0%
Net Earnings	-$10.58M	-$10.08M	$4.819M
YoY Change	-319.5%	-24.43%
Net Earnings / Revenue	-3.87%	-17.16%	3.19%
Basic Earnings Per Share	-$0.25	-$0.24
Diluted Earnings Per Share	-$0.25	-$0.24	$124.3K
COMMON SHARES
Basic Shares Outstanding	41.58M	41.58M
Diluted Shares Outstanding	41.58M	41.58M

Balance Sheet

Concept	2022 Q1	2021 Q4	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$110.3M	$140.5M	$1.290M
YoY Change	8453.94%
Cash & Equivalents	$110.3M	$140.5M	$1.285M
Short-Term Investments
Other Short-Term Assets	$7.100M	$7.315M	$160.0K
YoY Change	4337.36%
Inventory
Prepaid Expenses		$355.2K	$162.2K
Receivables	$95.36M	$51.34M
Other Receivables	$587.8K	$726.9K
Total Short-Term Assets	$213.4M	$199.9M	$1.448M
YoY Change	14641.18%	50502.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.329M	$8.048M
YoY Change		30.85%
Goodwill	$1.310B	$1.310B
YoY Change		150251.06%
Intangibles	$814.7M	$835.8M
YoY Change
Long-Term Investments
YoY Change
Other Assets		$10.61M	$316.3M
YoY Change
Total Long-Term Assets	$2.143B	$2.164B	$316.3M
YoY Change	577.71%
TOTAL ASSETS
Total Short-Term Assets	$213.4M	$199.9M	$1.448M
Total Long-Term Assets	$2.143B	$2.164B	$316.3M
Total Assets	$2.357B	$2.364B	$317.7M
YoY Change	641.79%	598469.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$19.70M	$124.5M
YoY Change
Accrued Expenses	$56.24M	$52.91M	$118.8K
YoY Change	47243.63%	2314469.99%
Deferred Revenue
YoY Change
Short-Term Debt	$2.394M	$3.579M
YoY Change
Long-Term Debt Due	$23.14K	$46.10K
YoY Change		-48.77%
Total Short-Term Liabilities	$234.4M	$198.8M	$175.6K
YoY Change	133376.64%	53298.41%
LONG-TERM LIABILITIES
Long-Term Debt	$80.00M	$80.00M
YoY Change		76.26%
Other Long-Term Liabilities	$27.15M	$21.17M	$5.840M
YoY Change	364.88%
Total Long-Term Liabilities	$107.1M	$101.2M	$5.840M
YoY Change	1734.75%	82.81%
TOTAL LIABILITIES
Total Short-Term Liabilities	$234.4M	$198.8M	$175.6K
Total Long-Term Liabilities	$107.1M	$101.2M	$5.840M
Total Liabilities	$341.6M	$299.9M	$6.013M
YoY Change	5579.97%	80475.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$50.00M	-$39.42M	$4.817M
YoY Change	-1137.97%	1724227.38%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$263.0M	$273.6M	$5.000M
YoY Change
Total Liabilities & Shareholders Equity	$2.357B	$2.364B	$317.7M
YoY Change	641.79%	598469.09%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021 Q1
OPERATING ACTIVITIES
Net Income	-$10.58M	-$10.08M	$4.819M
YoY Change	-319.5%	-24.43%
Depreciation, Depletion And Amortization	$590.5K	$187.6K	$332.5K
YoY Change	77.58%	3.14%
Cash From Operating Activities	-$27.78M	-$15.34M	-$293.5K
YoY Change	9363.45%	-14.53%
INVESTING ACTIVITIES
Capital Expenditures	$877.2K	$120.6K	$656.2K
YoY Change	33.68%	-117.37%
Acquisitions
YoY Change
Other Investing Activities	-$272.2K	-$47.76M	-$316.3M
YoY Change	-99.91%	8196.58%
Cash From Investing Activities	-$1.149M	-$47.86M	-$316.3M
YoY Change	-99.64%	3669.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$22.96K	$8.008K
YoY Change
Cash From Financing Activities	-1.207M	198.7M	317.6M
YoY Change	-100.38%	471.21%
NET CHANGE
Cash From Operating Activities	-27.78M	-15.34M	-293.5K
Cash From Investing Activities	-1.149M	-47.86M	-316.3M
Cash From Financing Activities	-1.207M	198.7M	317.6M
Net Change In Cash	-30.13M	135.5M	1.106M
YoY Change	-2824.77%	770.6%
FREE CASH FLOW
Cash From Operating Activities	-$27.78M	-$15.34M	-$293.5K
Capital Expenditures	$877.2K	$120.6K	$656.2K
Free Cash Flow	-$28.65M	-$15.46M	-$949.7K
YoY Change	2917.05%	-10.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-10577504
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41578890
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001832511
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrent
CY2021Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q1	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2021Q1	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	84000000
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	84000000
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	84000000
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	84000000
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Entity File Number EntityFileNumber	001-40033
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	P3 Health Partners Inc.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-2992794
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	2370 Corporate Circle Suite 300
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Henderson
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	89074
CY2022Q1	dei	City Area Code CityAreaCode	702
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	910-3950
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	110345801
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	140477586
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	356242
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	356286
CY2022Q1	piii	Health Plan Settlement Receivables Current HealthPlanSettlementReceivablesCurrent	94587702
CY2021Q4	piii	Health Plan Settlement Receivables Current HealthPlanSettlementReceivablesCurrent	50251004
CY2022Q1	piii	Clinic Fees And Insurance Receivables Net Current ClinicFeesAndInsuranceReceivablesNetCurrent	767396
CY2021Q4	piii	Clinic Fees And Insurance Receivables Net Current ClinicFeesAndInsuranceReceivablesNetCurrent	1090104
CY2022Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	587833
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	726903
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6743525
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6959067
CY2022Q1	us-gaap	Assets Current AssetsCurrent	213388499
CY2021Q4	us-gaap	Assets Current AssetsCurrent	199860950
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9085895
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8230250
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	757158
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	182321
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8328737
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8047929
CY2022Q1	us-gaap	Goodwill Goodwill	1309750216
CY2021Q4	us-gaap	Goodwill Goodwill	1309750216
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	814677323
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	835838605
CY2022Q1	piii	Notes Receivable Noncurrent NotesReceivableNoncurrent	3561508
CY2021Q4	piii	Notes Receivable Noncurrent NotesReceivableNoncurrent	3590715
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6933928
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7020045
CY2022Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	2143251712
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	2164247510
CY2022Q1	us-gaap	Assets Assets	2356640211
CY2021Q4	us-gaap	Assets Assets	2364108460
CY2022Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	21726910
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	17730683
CY2022Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	7686205
CY2022Q1	us-gaap	Depreciation Depreciation	590549
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	6304362
CY2022Q1	piii	Health Plans Settlements Payable Current HealthPlansSettlementsPayableCurrent	18640013
CY2021Q4	piii	Health Plans Settlements Payable Current HealthPlansSettlementsPayableCurrent	22548694
CY2022Q1	piii	Claims Payable Current ClaimsPayableCurrent	137407952
CY2021Q4	piii	Claims Payable Current ClaimsPayableCurrent	101958324
CY2022Q1	piii	Premium Deficiency Reserve Current PremiumDeficiencyReserveCurrent	36511129
CY2021Q4	piii	Premium Deficiency Reserve Current PremiumDeficiencyReserveCurrent	37835642
CY2022Q1	us-gaap	Interest Payable Current InterestPayableCurrent	10011573
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	8771065
CY2022Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	23144
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	46101
CY2022Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	2394079
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	3578561
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	234401005
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	198773432
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6327733
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6296883
CY2022Q1	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	17244101
CY2021Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	11382826
CY2022Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3577417
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3486593
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	80000000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	80000000
CY2022Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	107149251
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	101166302
CY2022Q1	us-gaap	Liabilities Liabilities	341550256
CY2021Q4	us-gaap	Liabilities Liabilities	299939734
CY2022Q1	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	1752115963
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	1790617285
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	312945752
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	312945752
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-49995628
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39418124
CY2022Q1	us-gaap	Limited Liability Company Llc Members Equity Including Portion Attributable To Noncontrolling Interest LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest	262973992
CY2021Q4	us-gaap	Limited Liability Company Llc Members Equity Including Portion Attributable To Noncontrolling Interest LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest	273551441
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2356640211
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2364108460
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	273544334
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	151297940
CY2022Q1	piii	Medical Expenses MedicalExpenses	265820802
CY2021Q1	piii	Medical Expenses MedicalExpenses	146624505
CY2022Q1	piii	Premium Deficiency Testing Expense Long Duration Contract Amount1 PremiumDeficiencyTestingExpenseLongDurationContractAmount1	-1324513
CY2021Q1	piii	Premium Deficiency Testing Expense Long Duration Contract Amount1 PremiumDeficiencyTestingExpenseLongDurationContractAmount1	2000000
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	38599412
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15059076
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	864530
CY2021Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	270241
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21161282
CY2021Q1	us-gaap	Depreciation Depreciation	332548
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	325712062
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	164286370
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-52167728
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-12988430
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-2761250
CY2021Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-2124286
CY2022Q1	piii	Mark To Market Adjustment Of Stock Warrants MarkToMarketAdjustmentOfStockWarrants	5861276
CY2021Q1	piii	Mark To Market Adjustment Of Stock Warrants MarkToMarketAdjustmentOfStockWarrants	9537996
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8622526
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-11662282
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-60790254
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24650712
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-60790254
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-24650712
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-50212750
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-10577504
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-24650712
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2020Q4	us-gaap	Limited Liability Company Llc Members Equity Including Portion Attributable To Noncontrolling Interest LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest	-130217705
CY2021Q1	us-gaap	Partners Capital Account Unit Based Compensation PartnersCapitalAccountUnitBasedCompensation	460515
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-24650712
CY2021Q1	us-gaap	Limited Liability Company Llc Members Equity Including Portion Attributable To Noncontrolling Interest LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest	-154407902
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	273551441
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	55
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-10577504
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	262973992
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-60790254
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-24650712
CY2022Q1	us-gaap	Depreciation Depreciation	590549
CY2021Q1	us-gaap	Depreciation Depreciation	332548
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21161282
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	11711428
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	460515
CY2021Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	310653
CY2022Q1	piii	Mark To Market Adjustment Of Stock Warrants MarkToMarketAdjustmentOfStockWarrants	5861276
CY2021Q1	piii	Mark To Market Adjustment Of Stock Warrants MarkToMarketAdjustmentOfStockWarrants	9537996
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	171936
CY2022Q1	piii	Premium Deficiency Testing Expense Long Duration Contract Amount1 PremiumDeficiencyTestingExpenseLongDurationContractAmount1	-1324513
CY2021Q1	piii	Premium Deficiency Testing Expense Long Duration Contract Amount1 PremiumDeficiencyTestingExpenseLongDurationContractAmount1	2000000
CY2022Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	90824
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-805178
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	46822
CY2022Q1	piii	Increase Decrease In Health Plan Receivables Premiums IncreaseDecreaseInHealthPlanReceivablesPremiums	44336698
CY2021Q1	piii	Increase Decrease In Health Plan Receivables Premiums IncreaseDecreaseInHealthPlanReceivablesPremiums	8235713
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-215542
CY2021Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	5931
CY2022Q1	piii	Net Change In Right Of Use Assets And Liabilities NetChangeInRightOfUseAssetsAndLiabilities	-58423
CY2021Q1	piii	Net Change In Right Of Use Assets And Liabilities NetChangeInRightOfUseAssetsAndLiabilities	-9014
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	4018630
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	85555
CY2022Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	1381843
CY2021Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	710148
CY2022Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	1240508
CY2021Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	874850
CY2022Q1	piii	Increase Decrease In Health Plan Payables Premiums IncreaseDecreaseInHealthPlanPayablesPremiums	-3908681
CY2021Q1	piii	Increase Decrease In Health Plan Payables Premiums IncreaseDecreaseInHealthPlanPayablesPremiums	1988897
CY2022Q1	piii	Increase Decrease In Claims Payables IncreaseDecreaseInClaimsPayables	35449628
CY2021Q1	piii	Increase Decrease In Claims Payables IncreaseDecreaseInClaimsPayables	3335346
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27775035
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13121720
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	877165
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	656177
CY2022Q1	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable	272190
CY2021Q1	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable	73495
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1149355
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-729672
CY2022Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	1207439
CY2021Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	22224
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1207439
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-22224
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-30131829
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13873616
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	140833872
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39902947
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110702043
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26029331
CY2022Q1	piii	Number Of Health Plans Agreements Entered NumberOfHealthPlansAgreementsEntered	20
CY2021Q4	piii	Number Of Health Plans Agreements Entered NumberOfHealthPlansAgreementsEntered	17
CY2022Q1	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.080
CY2022Q1	piii	Preferred Returns PreferredReturns	8
CY2021Q1	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.08
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-60790254
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24650712
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	110345801
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	140477586
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	140477586
CY2022Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Management’s Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Preparation of these condensed consolidated financial statements and accompanying footnotes, in conformity with U.S. GAAP, requires Management to make estimates and assumptions that could affect amounts reported here. Management bases its estimates on the best information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID 19. See Note 23 “Commitments and Contingencies” for further discussion on the impact of COVID-19.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The areas where significant estimates are used in these accompanying condensed consolidated financial statements include revenue recognition, the liability for unpaid claims, unit-based and share-based compensation, premium deficiency reserves (“PDR”), fair value and impairment recognition of long-lived assets (including intangible assets and goodwill), fair value of acquired assets and liabilities in Business Combinations, fair value of liability classified instruments and judgments related to deferred income taxes. Actual results could differ from those estimates.</p>
CY2022Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	110345801
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	110345801
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	140477586
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	356242
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	356286
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110702043
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	140833872
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22341413
CY2021Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	3687918
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26029331
CY2022Q1	us-gaap	Revenue Practical Expedient Financing Component RevenuePracticalExpedientFinancingComponent	true
CY2022Q1	piii	Health Plans Term Of Contract HealthPlansTermOfContract	P1M
CY2022Q1	piii	Number Of Health Plans Percentage Of Payment Contracts Entered NumberOfHealthPlansPercentageOfPaymentContractsEntered	20
CY2022Q1	piii	Number Of States NumberOfStates	5
CY2021Q4	piii	Number Of Health Plans Percentage Of Payment Contracts Entered NumberOfHealthPlansPercentageOfPaymentContractsEntered	17
CY2021Q4	piii	Number Of States NumberOfStates	4
CY2022Q1	piii	Term For Reconciliation And Distribution Of Reserve Following End Of Each Quarter TermForReconciliationAndDistributionOfReserveFollowingEndOfEachQuarter	P120D
CY2022Q1	piii	Term For Reconciliation And Distribution Of Reserve Following Each Year End TermForReconciliationAndDistributionOfReserveFollowingEachYearEnd	P21M
CY2022Q1	piii	Health Plans Settlements Payable Current HealthPlansSettlementsPayableCurrent	18640013
CY2021Q4	piii	Health Plans Settlements Payable Current HealthPlansSettlementsPayableCurrent	22548694
CY2022Q1	piii	Number Of Revenue Practical Expedients Elected NumberOfRevenuePracticalExpedientsElected	2
CY2022Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2021Q1	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	186188678
CY2021Q1	us-gaap	Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax	-72130030
CY2021Q1	piii	Business Acquisition Pro Forma Net Income Loss Attributable To Noncontrolling Interest BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest	-59579405
CY2021Q1	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-12550625
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	110345801
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	140477586
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	356242
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	356286
CY2022Q1	piii	Clinic Fees And Insurance Receivables Net Current ClinicFeesAndInsuranceReceivablesNetCurrent	767396
CY2021Q4	piii	Clinic Fees And Insurance Receivables Net Current ClinicFeesAndInsuranceReceivablesNetCurrent	1090104
CY2022Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	587833
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	726903
CY2022Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	21726910
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	17730683
CY2022Q1	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	17244101
CY2021Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	11382826
CY2022Q1	us-gaap	Contract With Customer Receivable Before Allowance For Credit Loss Current ContractWithCustomerReceivableBeforeAllowanceForCreditLossCurrent	2669300
CY2021Q4	us-gaap	Contract With Customer Receivable Before Allowance For Credit Loss Current ContractWithCustomerReceivableBeforeAllowanceForCreditLossCurrent	2641182
CY2022Q1	us-gaap	Contract With Customer Receivable Allowance For Credit Loss Current ContractWithCustomerReceivableAllowanceForCreditLossCurrent	2157418
CY2021Q4	us-gaap	Contract With Customer Receivable Allowance For Credit Loss Current ContractWithCustomerReceivableAllowanceForCreditLossCurrent	1968750
CY2022Q1	us-gaap	Contract With Customer Receivable After Allowance For Credit Loss Current ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent	511882
CY2021Q4	us-gaap	Contract With Customer Receivable After Allowance For Credit Loss Current ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent	672432
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9085895
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8230250
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	757158
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	182321
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8328737
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8047929
CY2022Q1	us-gaap	Goodwill Goodwill	1309750216
CY2021Q4	us-gaap	Goodwill Goodwill	1309750216
CY2022Q1	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0
CY2021Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2022Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2022Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	851500000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	835838605
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21161282
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	814677323
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	84000000
CY2022Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P9Y8M12D
CY2022Q1	piii	Financing Receivable Number Of Promissory Notes Entered FinancingReceivableNumberOfPromissoryNotesEntered	5
CY2022Q1	piii	Financing Receivable Number Of Family Medical Practices With Whom Promissory Notes Are Entered FinancingReceivableNumberOfFamilyMedicalPracticesWithWhomPromissoryNotesAreEntered	3
CY2022Q1	piii	Financing Receivable Separate Provider Agreements With Each Practice Related To Number Of Promissory Notes Entered FinancingReceivableSeparateProviderAgreementsWithEachPracticeRelatedToNumberOfPromissoryNotesEntered	4
CY2022Q1	piii	Financing Receivable Number Of Separate Provider Agreements Entered With Each Practice FinancingReceivableNumberOfSeparateProviderAgreementsEnteredWithEachPractice	5
CY2022Q1	piii	Financing Receivable Separate Provider Agreements With Each Practice Related To Number Of Promissory Notes Entered FinancingReceivableSeparateProviderAgreementsWithEachPracticeRelatedToNumberOfPromissoryNotesEntered	4
CY2022Q1	us-gaap	Notes Receivable Net NotesReceivableNet	3561508
CY2021Q4	us-gaap	Notes Receivable Net NotesReceivableNet	3590715
CY2022Q1	us-gaap	Financing Receivable Accrued Interest Before Allowance For Credit Loss FinancingReceivableAccruedInterestBeforeAllowanceForCreditLoss	967176
CY2021Q4	us-gaap	Financing Receivable Accrued Interest Before Allowance For Credit Loss FinancingReceivableAccruedInterestBeforeAllowanceForCreditLoss	885243
CY2022Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	609821
CY2021Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	526808
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	137407952
CY2021Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	101958324
CY2022Q1	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;"></span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:79.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:79.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:79.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Claims Unpaid, Beginning of Period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 101,958,324</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:79.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Incurred, Related to:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:79.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Current Period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 234,493,077</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:79.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Prior Period(s)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,331,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:79.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Incurred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 237,824,819</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:79.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Paid, Related to:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:79.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Current Period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 118,045,532</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:79.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Prior Period(s)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,329,659</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:79.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 202,375,191</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:79.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Claims Unpaid Assumed in Acquisitions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:79.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Claims Unpaid, End of Period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 137,407,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr></table>
CY2021Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	101958324
CY2022Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	234493077
CY2022Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	3331742
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	237824819
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	118045532
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	84329659
CY2022Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	202375191
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	137407952
CY2022Q1	piii	Paid In Kind Interest Payment Term PaidInKindInterestPaymentTerm	P3Y
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	80046101
CY2022Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	22957
CY2022Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	80023144
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	23144
CY2022Q1	piii	Long Term Debt Paid In Kind Interest Maturity Remainder Of Fiscal Year LongTermDebtPaidInKindInterestMaturityRemainderOfFiscalYear	3954949
CY2022Q1	piii	Long Term Debt Cash Interest Maturity Remainder Of Fiscal Year LongTermDebtCashInterestMaturityRemainderOfFiscalYear	4161790
CY2022Q1	piii	Long Term Debt Total Payments Maturity Remainder Of Fiscal Year LongTermDebtTotalPaymentsMaturityRemainderOfFiscalYear	4184934
CY2022Q1	piii	Long Term Debt Paid In Kind Interest Maturity Year One LongTermDebtPaidInKindInterestMaturityYearOne	5624513
CY2022Q1	piii	Long Term Debt Cash Interest Maturity Year One LongTermDebtCashInterestMaturityYearOne	5675461
CY2022Q1	piii	Long Term Debt Total Payments Maturity Year One LongTermDebtTotalPaymentsMaturityYearOne	5675461
CY2022Q1	piii	Long Term Debt Paid In Kind Interest Maturity Year Two LongTermDebtPaidInKindInterestMaturityYearTwo	6061814
CY2022Q1	piii	Long Term Debt Cash Interest Maturity Year Two LongTermDebtCashInterestMaturityYearTwo	5882309
CY2022Q1	piii	Long Term Debt Total Payments Maturity Year Two LongTermDebtTotalPaymentsMaturityYearTwo	5882309
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	65000000
CY2022Q1	piii	Long Term Debt Paid In Kind Interest Maturity Year Three LongTermDebtPaidInKindInterestMaturityYearThree	6274526
CY2022Q1	piii	Long Term Debt Cash Interest Maturity Year Three LongTermDebtCashInterestMaturityYearThree	19518225
CY2022Q1	piii	Long Term Debt Total Payments Maturity Year Three LongTermDebtTotalPaymentsMaturityYearThree	84518225
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	15000000
CY2022Q1	piii	Premium Deficiency Reserve Current PremiumDeficiencyReserveCurrent	36511129
CY2021Q4	piii	Premium Deficiency Reserve Current PremiumDeficiencyReserveCurrent	37835642
CY2022Q1	piii	Number Of New Operating Lease NumberOfNewOperatingLease	1
	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	83000000
CY2022Q1	piii	Long Term Debt Paid In Kind Interest Maturity Year Four LongTermDebtPaidInKindInterestMaturityYearFour	1851284
CY2022Q1	piii	Long Term Debt Cash Interest Maturity Year Four LongTermDebtCashInterestMaturityYearFour	20054451
CY2022Q1	piii	Long Term Debt Total Payments Maturity Year Four LongTermDebtTotalPaymentsMaturityYearFour	35054451
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	80023144
CY2022Q1	piii	Long Term Debt Paid In Kind Interest Maturity LongTermDebtPaidInKindInterestMaturity	23767086
CY2022Q1	piii	Long Term Debt Cash Interest Maturity LongTermDebtCashInterestMaturity	55292236
CY2022Q1	piii	Long Term Debt Total Payments Maturity LongTermDebtTotalPaymentsMaturity	135315380
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	80023144
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	80046101
CY2022Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	23144
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	46101
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	80000000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	80000000
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2021Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2022Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q1	piii	Estimated Future Tax Benefits EstimatedFutureTaxBenefits	0.85
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q1	us-gaap	Common Unit Outstanding CommonUnitOutstanding	41578890
CY2021Q4	us-gaap	Common Unit Outstanding CommonUnitOutstanding	41578890
CY2022Q1	piii	Redeemable Noncontrolling Interest Equity Fair Value Remeasurement Adjustment RedeemableNoncontrollingInterestEquityFairValueRemeasurementAdjustment	0
CY2021	piii	Redeemable Noncontrolling Interest Equity Fair Value Remeasurement Adjustment RedeemableNoncontrollingInterestEquityFairValueRemeasurementAdjustment	0
CY2021	piii	Number Of Health Plans Resulting In Renegotiation NumberOfHealthPlansResultingInRenegotiation	1
CY2022Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	10600000
CY2022Q1	piii	Percentage Of Total Revenues Recurring PercentageOfTotalRevenuesRecurring	0.97
CY2021	piii	Percentage Of Total Revenues Recurring PercentageOfTotalRevenuesRecurring	0.97
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	12886535
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2034279
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.43
CY2022Q1	piii	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P2Y11M26D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2034279
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.43
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y11M26D
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2121248
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1911705
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-60790254
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-50212750
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10577504
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41578890
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17875024
CY2020Q4	piii	Premium Deficiency Reserve Current PremiumDeficiencyReserveCurrent	0
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	736535
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	488312
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y11M15D
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M8D
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1122
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1030
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2028692
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1631163
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1089562
CY2022Q1	piii	Lessee Operating Lease Liability Payments After Year Four LesseeOperatingLeaseLiabilityPaymentsAfterYearFour	2240230
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	11022600
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2666176
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	8356424
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2028691
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2087235
CY2021Q4	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	24110831
CY2022Q1	us-gaap	Loans And Leases Receivable Related Parties Additions LoansAndLeasesReceivableRelatedPartiesAdditions	1367151
CY2022Q1	us-gaap	Loans And Leases Receivable Related Parties Period Increase Decrease LoansAndLeasesReceivableRelatedPartiesPeriodIncreaseDecrease	404315
CY2022Q1	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	25882297

Files In Submission

Name	View Source	Status
0001558370-22-015155-index-headers.html	Edgar Link	pending
0001558370-22-015155-index.html	Edgar Link	pending
0001558370-22-015155.txt	Edgar Link	pending
0001558370-22-015155-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
piii-20220331.xsd	Edgar Link	pending
piii-20220331x10q.htm	Edgar Link	pending
piii-20220331xex31d1.htm	Edgar Link	pending
piii-20220331xex31d2.htm	Edgar Link	pending
piii-20220331xex32d1.htm	Edgar Link	pending
piii-20220331xex32d2.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
piii-20220331_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
piii-20220331_def.xml	Edgar Link	unprocessable
piii-20220331_lab.xml	Edgar Link	unprocessable
piii-20220331_pre.xml	Edgar Link	unprocessable
piii-20220331x10q_htm.xml	Edgar Link	completed
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PIII
P3 Health Partners Inc. Stock $piii

2022 Q1 Form 10-Q Financial Statement

#000155837022015155 Filed on October 21, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIII P3 Health Partners Inc. Stock $piii

2022 Q1 Form 10-Q Financial Statement

#000155837022015155 Filed on October 21, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIII
P3 Health Partners Inc. Stock $piii